Colibri Heart Valve Announces Issuance of a Patent for New Heart Valve on a Delivery System

Patent Granted for a Pre-mounted, Pre-packaged, Sterilized Dry Heart Valve on a Delivery System

BROOMFIELD, CO, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve,
LLC, a privately held medical device company, has been granted yet
another patent directed to prosthetic heart valves. More particularly,
today the U.S. Patent & Trademark Office granted Colibri U.S. Patent
No. 8,361,144 entitled, "Percutaneously Deliverable Heart Valve Device
And Methods Associated Therewith." The patent is directed to a method
of making a pre-packaged, sterilized, dry heart valve pre-mounted on a
delivery system. The patent provides Colibri with intellectual property
rights extending into 2031 for the significant medical device market
concerning prosthetic heart valves. Colibri is also seeking patent
rights in a number of foreign countries.

"With the recent issuance of this patent and the successful
first-in-human implantation of the Colibri ready-to-use TAVI system,
which is reflected in this patent, we believe Colibri has a meaningful
opportunity in the THV market," said Joseph B. Horn, Colibri's
president and chief executive officer. "The broad claims in this
recently allowed patent provides us with the coverage to expand the
Colibri pre-packaged, pre-mounted, dry valve technology into all heart
valve applications."

For more information on the first-in-human implantation, please visit
the Valve Implantation page of the Colibri Heart Valve website.

About the Colibri Heart Valve and the Ready-to-Use Colibri TAVI System

Colibri Heart Valve, LLC is a privately held medical device company
based in Broomfield, CO that researches and develops novel heart valve
technologies. Colibri has developed a pre-mounted, pre-crimped, and
pre-packaged, ready-for-use transcatheter aortic valve implantation
(TAVI) device called the "Colibri TAVI System." TAVI is an important
treatment option for heart valve replacement due to its minimally
invasive nature, clinical efficacy, extensive patient experience, and
reduced procedural costs. Colibri's advanced technology is a
culmination of over 10 years of research and development by Colibri's
founders, Dr. David Paniagua and Dr. R. David Fish into the tissue,
valve design, frame, and delivery catheter. Colibri's unique tissue
processing method produces extremely strong, durable, and biocompatible
tissue. The proprietary tissue enables loading, crimping, and packaging
of the Colibri valve at manufacture, making in-procedure valve rinsing
and loading at time of use unnecessary. The "Colibri TAVI System" is
designed to be shipped ready-for-use.

Colibri's corporate headquarters and pre-commercialization facilities
are located in Broomfield, Colorado with R&D located in Houston, Texas.
For more information, visit: www.colibrihv.com.

CONTACT: Eric Schauble, VP, Corporate Development
Colibri Heart Valve, LLC
(303) 460-8667
eschauble@colibrihv.com

Aline Schimmel
Scienta Communications
(312) 238-8957
aschimmel@scientapr.com